Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

COREY J HEBERT

Allopathic & Osteopathic Physicians Pediatrics

NPI
1457368037
CMS profile
111631
Location
GRETNA, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$334,588.63

189 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 189 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

COREY J HEBERT

NPI 1457368037 · CMS profile ID 111631

Allopathic & Osteopathic Physicians / Pediatrics

GRETNA, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 189 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1457368037?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
COREY J HEBERT, NPI 1457368037, CMS profile ID 111631. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 189 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1457368037?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). COREY J HEBERT, NPI 1457368037, CMS profile ID 111631. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 189 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1457368037?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
COREY J HEBERT, NPI 1457368037, CMS profile ID 111631, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 189 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1457368037?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

189 matching records · $334,588.63 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 189 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 189.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $97.6605/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116627758 CMS
GlaxoSmithKline, LLC. $205.4605/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116702043 CMS
Emmaus Medical, Inc. $15,100.0005/20/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1073839722 CMS
GlaxoSmithKline, LLC. $54.7205/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115946229 CMS
GlaxoSmithKline, LLC. $3,900.0005/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116084825 CMS
GlaxoSmithKline, LLC. $69.6805/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116257152 CMS
GlaxoSmithKline, LLC. $3,900.0005/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116323474 CMS
GlaxoSmithKline, LLC. $1,423.9705/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116316674 CMS
GlaxoSmithKline, LLC. $110.5105/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116503291 CMS
GlaxoSmithKline, LLC. $147.6105/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116734418 CMS
GlaxoSmithKline, LLC. $1,300.0005/10/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116176646 CMS
GlaxoSmithKline, LLC. $834.3705/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116199119 CMS
GlaxoSmithKline, LLC. $3,900.0005/10/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116519124 CMS
GlaxoSmithKline, LLC. $230.8505/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116619759 CMS
GlaxoSmithKline, LLC. $208.1305/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116239453 CMS
GlaxoSmithKline, LLC. $1,121.9005/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116537052 CMS
GlaxoSmithKline, LLC. $123.1405/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116669162 CMS
GlaxoSmithKline, LLC. $26.0005/08/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116422789 CMS
GlaxoSmithKline, LLC. $6.0005/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116583789 CMS
GlaxoSmithKline, LLC. $26.0005/08/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116670252 CMS
GlaxoSmithKline, LLC. $306.3705/08/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116690405 CMS
Supernus Pharmaceuticals, Inc. $205.0005/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147779532 CMS
Supernus Pharmaceuticals, Inc. $257.0105/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147779536 CMS
Supernus Pharmaceuticals, Inc. $346.9605/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147779538 CMS
Supernus Pharmaceuticals, Inc. $2,750.0005/03/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147779542 CMS
Supernus Pharmaceuticals, Inc. $67.1005/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147779526 CMS
Supernus Pharmaceuticals, Inc. $87.0905/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147779528 CMS
Supernus Pharmaceuticals, Inc. $97.1305/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147779530 CMS
Supernus Pharmaceuticals, Inc. $222.7705/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147779534 CMS
Supernus Pharmaceuticals, Inc. $387.0105/02/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147779540 CMS
GlaxoSmithKline, LLC. $88.9604/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115735948 CMS
GlaxoSmithKline, LLC. $104.0004/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116684151 CMS
GlaxoSmithKline, LLC. $297.1804/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116099315 CMS
GlaxoSmithKline, LLC. $642.2004/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116249741 CMS
GlaxoSmithKline, LLC. $125.0004/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116519790 CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. $58.8004/22/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118837147 CMS
GlaxoSmithKline, LLC. $120.8904/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115861926 CMS
GlaxoSmithKline, LLC. $1,684.5604/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116339858 CMS
GlaxoSmithKline, LLC. $214.9804/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116516898 CMS
Emmaus Medical, Inc. $60,400.0004/10/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1073839720 CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. $10,530.0004/08/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118837145 CMS
IRONSHORE PHARMACEUTICALS INC. $6,742.5004/05/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146245195 CMS
IRONSHORE PHARMACEUTICALS INC. $31.0804/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146246835 CMS
IRONSHORE PHARMACEUTICALS INC. $72.0004/05/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146260703 CMS
GlaxoSmithKline, LLC. $3,900.0004/01/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116016147 CMS
GlaxoSmithKline, LLC. $650.0004/01/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116257460 CMS
GlaxoSmithKline, LLC. $3,900.0004/01/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116474105 CMS
GlaxoSmithKline, LLC. $1,300.0004/01/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116479675 CMS
GlaxoSmithKline, LLC. $121.8803/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115896276 CMS
GlaxoSmithKline, LLC. $1,080.6503/28/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116534556 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $8,518.79 28
PY2020 $19,061.50 21
PY2021 $139,881.01 149
PY2022 $424,823.42 182
PY2023 $229,662.16 172
PY2024 $334,588.63 189
PY2025 $132,206.82 133

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $372,405.31 132
PY2024 Recipient $985.28 10
PY2024 Principal investigator $934,034.65 82
PY2023 Recipient $6,302.70 4
PY2023 Principal investigator $477,308.92 450
PY2022 Principal investigator $268,266.34 21
PY2021 Recipient $492,575.00 2
PY2021 Principal investigator $2,325,868.63 45
PY2020 Recipient $938,471.67 2
PY2020 Principal investigator $44,551.99 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

132 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $9,159.50 12/19/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997239
Principal investigator 1 ModernaTX, Inc. $4,579.75 11/27/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997227
Principal investigator 1 PFIZER INC. $10,062.00 11/20/2025 Non-covered Recipient Entity
Avant Trials LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228727945
Principal investigator 1 ModernaTX, Inc. $1,798.00 11/17/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997237
Principal investigator 1 ModernaTX, Inc. $1,736.00 11/17/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997423
Principal investigator 1 ModernaTX, Inc. $4,420.52 10/29/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997249
Principal investigator 1 ModernaTX, Inc. $29.88 10/29/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997269
Principal investigator 1 ModernaTX, Inc. $13,250.93 10/29/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997303
Principal investigator 1 ModernaTX, Inc. $3,369.46 10/29/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997329
Principal investigator 1 ModernaTX, Inc. $1,291.62 10/29/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997339
Principal investigator 1 ModernaTX, Inc. $6,007.32 10/29/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997351
Principal investigator 1 ModernaTX, Inc. $883.86 10/29/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997369
Principal investigator 1 ModernaTX, Inc. $9,538.48 10/29/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997371
Principal investigator 1 ModernaTX, Inc. $1,572.63 10/29/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997393
Principal investigator 1 ModernaTX, Inc. $2,738.66 10/29/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997397
Principal investigator 1 ModernaTX, Inc. $11,907.35 10/29/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997425
Principal investigator 1 ModernaTX, Inc. $4,444.10 10/29/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997441
Principal investigator 1 ModernaTX, Inc. $5,061.22 10/29/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997443
Principal investigator 1 ModernaTX, Inc. $9,268.38 10/29/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997453
Principal investigator 1 ModernaTX, Inc. $2,730.42 10/29/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997459
Principal investigator 1 ModernaTX, Inc. $4,922.52 10/29/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997461
Principal investigator 1 ModernaTX, Inc. $4,597.60 10/29/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997481
Principal investigator 1 PFIZER INC. $4,023.00 10/09/2025 Non-covered Recipient Entity
Avant Trials LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228730983
Principal investigator 1 ModernaTX, Inc. $2,946.20 09/29/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997295
Principal investigator 1 ModernaTX, Inc. $2,000.00 09/03/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997275
Principal investigator 1 ModernaTX, Inc. $3,240.82 08/28/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997231
Principal investigator 1 ModernaTX, Inc. $17,556.88 07/02/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997391
Principal investigator 1 ModernaTX, Inc. $915.95 06/30/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997241
Principal investigator 1 ModernaTX, Inc. $2,946.20 06/30/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997365
Principal investigator 1 ModernaTX, Inc. $10,075.45 06/23/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997299
Principal investigator 1 ModernaTX, Inc. $3,240.82 06/23/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997305
Principal investigator 1 PFIZER INC. $1,350.00 06/13/2025 Non-covered Recipient Entity
Avant Trials LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228774883
Principal investigator 1 ModernaTX, Inc. $8,432.41 05/28/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997229
Principal investigator 1 ModernaTX, Inc. $2,356.96 05/28/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997293
Principal investigator 1 ModernaTX, Inc. $7,327.60 05/28/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997429
Principal investigator 1 ModernaTX, Inc. $145.20 05/26/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997331
Principal investigator 1 ModernaTX, Inc. $7,491.00 05/15/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997257
Principal investigator 1 ModernaTX, Inc. $1,000.00 05/15/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997415
Principal investigator 1 ModernaTX, Inc. $5,642.00 05/15/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997433
Principal investigator 1 ModernaTX, Inc. $620.00 05/12/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997243
Principal investigator 1 ModernaTX, Inc. $248.00 05/12/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997291
Principal investigator 1 ModernaTX, Inc. $682.00 05/12/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997297
Principal investigator 1 ModernaTX, Inc. $930.00 05/12/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997307
Principal investigator 1 ModernaTX, Inc. $1,364.00 05/12/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997463
Principal investigator 1 ModernaTX, Inc. $110.00 05/08/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997259
Principal investigator 1 ModernaTX, Inc. $33.00 05/08/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997389
Principal investigator 1 ModernaTX, Inc. $382.80 05/08/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997399
Principal investigator 1 ModernaTX, Inc. $184.80 05/08/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997445
Principal investigator 1 ModernaTX, Inc. $900.00 05/08/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997465
Principal investigator 1 ModernaTX, Inc. $3,418.80 05/08/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997471
Principal investigator 1 ModernaTX, Inc. $20,974.80 04/30/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997281
Principal investigator 1 ModernaTX, Inc. $4,818.52 04/28/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997247
Principal investigator 1 ModernaTX, Inc. $8,243.55 04/28/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997301
Principal investigator 1 ModernaTX, Inc. $2,946.20 04/28/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997367
Principal investigator 1 ModernaTX, Inc. $12,768.64 04/28/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997385
Principal investigator 1 ModernaTX, Inc. $770.00 04/25/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997315
Principal investigator 1 ModernaTX, Inc. $2,800.00 04/21/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997261
Principal investigator 1 ModernaTX, Inc. $520.00 04/21/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997273
Principal investigator 1 ModernaTX, Inc. $563.64 04/21/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997409
Principal investigator 1 ModernaTX, Inc. $633.60 04/21/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997411
Principal investigator 1 ModernaTX, Inc. $800.00 04/10/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997323
Principal investigator 1 ModernaTX, Inc. $4,494.60 04/10/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997413
Principal investigator 1 ModernaTX, Inc. $868.00 04/07/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997349
Principal investigator 1 ModernaTX, Inc. $660.00 04/07/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997395
Principal investigator 1 ModernaTX, Inc. $20.00 04/04/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997325
Principal investigator 1 ModernaTX, Inc. $356.40 04/04/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997327
Principal investigator 1 ModernaTX, Inc. $369.60 04/04/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997345
Principal investigator 1 ModernaTX, Inc. $528.00 04/04/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997347
Principal investigator 1 ModernaTX, Inc. $1,293.60 04/04/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997431
Principal investigator 1 ModernaTX, Inc. $171.60 04/04/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997479
Principal investigator 1 ModernaTX, Inc. $191.40 04/02/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997267
Principal investigator 1 ModernaTX, Inc. $165.00 04/02/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997285
Principal investigator 1 ModernaTX, Inc. $871.60 04/02/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997311
Principal investigator 1 ModernaTX, Inc. $356.40 04/02/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997335
Principal investigator 1 ModernaTX, Inc. $538.48 04/02/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997377
Principal investigator 1 ModernaTX, Inc. $99.00 04/02/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997379
Principal investigator 1 ModernaTX, Inc. $85.80 04/02/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997435
Principal investigator 1 ModernaTX, Inc. $30.00 04/02/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997437
Principal investigator 1 ModernaTX, Inc. $2,217.60 04/02/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997449
Principal investigator 1 ModernaTX, Inc. $171.60 04/02/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997451
Principal investigator 1 ModernaTX, Inc. $2,200.00 04/02/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997469
Principal investigator 1 ModernaTX, Inc. $2,996.40 04/02/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997483
Principal investigator 1 ModernaTX, Inc. $171.60 04/01/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997255
Principal investigator 1 ModernaTX, Inc. $72.60 04/01/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997283
Principal investigator 1 ModernaTX, Inc. $170.00 04/01/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997287
Principal investigator 1 ModernaTX, Inc. $250.00 04/01/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997343
Principal investigator 1 ModernaTX, Inc. $1,523.20 04/01/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997353
Principal investigator 1 ModernaTX, Inc. $382.80 04/01/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997381
Principal investigator 1 ModernaTX, Inc. $880.00 04/01/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997447
Principal investigator 1 ModernaTX, Inc. $19.80 04/01/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997477
Principal investigator 1 ModernaTX, Inc. $1,473.10 03/25/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997235
Principal investigator 1 ModernaTX, Inc. $16,572.60 03/25/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997279
Principal investigator 1 ModernaTX, Inc. $761.60 03/25/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997355
Principal investigator 1 ModernaTX, Inc. $207.24 03/25/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997401
Principal investigator 1 ModernaTX, Inc. $451.40 03/25/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997467
Principal investigator 1 ModernaTX, Inc. $66.00 03/17/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997265
Principal investigator 1 ModernaTX, Inc. $13.20 03/17/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997313
Principal investigator 1 ModernaTX, Inc. $52.80 03/17/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997387
Principal investigator 1 ModernaTX, Inc. $290.00 03/13/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997341
Principal investigator 1 ModernaTX, Inc. $124.00 03/07/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997271
Principal investigator 1 ModernaTX, Inc. $2,996.40 03/07/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997321
Principal investigator 1 ModernaTX, Inc. $400.00 03/07/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997333
Principal investigator 1 ModernaTX, Inc. $998.00 03/06/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997407
Principal investigator 1 ModernaTX, Inc. $1,650.00 03/06/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997455
Principal investigator 1 ModernaTX, Inc. $2,613.60 02/27/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997245
Principal investigator 1 ModernaTX, Inc. $2,062.34 02/27/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997361
Principal investigator 1 ModernaTX, Inc. $4,971.78 02/24/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997277
Principal investigator 1 ModernaTX, Inc. $1,293.60 02/10/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997357
Principal investigator 1 ModernaTX, Inc. $1,204.63 02/05/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997359
Principal investigator 1 ModernaTX, Inc. $2,356.96 02/05/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997373
Principal investigator 1 ModernaTX, Inc. $1,831.90 02/05/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997419
Principal investigator 1 ModernaTX, Inc. $2,996.40 01/30/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997233
Principal investigator 1 ModernaTX, Inc. $200.00 01/30/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997251
Principal investigator 1 ModernaTX, Inc. $633.60 01/30/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997253
Principal investigator 1 ModernaTX, Inc. $316.80 01/30/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997421
Principal investigator 1 ModernaTX, Inc. $448.80 01/30/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997427
Principal investigator 1 ModernaTX, Inc. $883.86 01/27/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997363
Principal investigator 1 ModernaTX, Inc. $12,705.66 01/27/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997383
Principal investigator 1 ModernaTX, Inc. $4,137.80 01/27/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997405
Principal investigator 1 ModernaTX, Inc. $261.36 01/27/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997417
Principal investigator 1 ModernaTX, Inc. $2,340.36 01/27/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997475
Principal investigator 1 ModernaTX, Inc. $171.60 01/22/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997317
Principal investigator 1 ModernaTX, Inc. $1,523.20 01/22/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997375
Principal investigator 1 ModernaTX, Inc. $382.80 01/22/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997457
Principal investigator 1 ModernaTX, Inc. $19,476.60 01/20/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997309
Principal investigator 1 ModernaTX, Inc. $800.00 01/20/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997337
Principal investigator 1 ModernaTX, Inc. $356.40 01/20/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997403
Principal investigator 1 ModernaTX, Inc. $132.00 01/20/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997439
Principal investigator 1 ModernaTX, Inc. $280.00 01/20/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997473
Principal investigator 1 ModernaTX, Inc. $761.60 01/08/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997263
Principal investigator 1 ModernaTX, Inc. $85.80 01/08/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997289
Principal investigator 1 ModernaTX, Inc. $191.40 01/08/2025 Non-covered Recipient Entity
RESEARCH WORKS INC
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1252997319